The Saudi Food and Drug Authority (SFDA) organized a virtual training workshop for employees of the Bahraini National Health Regulatory Authority, entitled "Principles of Good Manufacturing Practice (GMP) and Inspection Procedures", as part of the continuous cooperation between SFDA and the Bahraini National Health Regulatory Authority
The Saudi Food and Drug Authority (SFDA) signed on April 12, 2022 a memorandum of cooperation (MoC) with the Saudi Epilepsy Society (SES). The MoC aims to promote and develope the professional, research work of professional specialists and educating the community about epilepsy diseases.
The MOC was signed by His Excellency SFDA’s CEO, Dr. Hisham bin Saad Aljadhey, and SES Chairman Dr. Faisal bin Aboud Al-Otaibi.
Warning Date
|
|
|---|---|
Manufacture Company
|
|
Warning Reason
|
|
Correction Actions
|
|
Advices to Consumer
|
|
The Saudi Food and Drug Authority (SFDA) has issued a decision to recall and suspend the registration of the product (RABEZOLE) for the two registered strengths of 20 mg and 10 mg, (Registration No 95-368-07 and 96-368-07). The products are marketed by Jamjoom Pharmaceuticals. The decision has been taken as the product was found to be not bioequivalent with the reference product.
To report sector-related issues
Call Centre 19999
The Saudi Food and Drug Authority (SFDA) has detected 19 facilities that violated the Law of Pharmaceutical Establishments and Preparations during January of 2022, due to their lack of commitment to provide pharmaceutical products to the local market.
| Publication Date |
|
| Applying Date |
2019-05-01
|
